However, the use of antiangiogenetic drugs and, more in general of targeted therapies, is increasingly growing in advanced diseases, thus resulting in long-term clinical benefit and disease control (e.g., anti-VEGFR and anti-EGFR in colorectal cancer, EGFR TKIs, and ALK inhibitors in lung cancer). The gene discussed is ALK; the disease is lung carcinoma.